Vascular Endothelial Growth Factor (VEGF) in the Pathogenesis of Diabetic Nephropathy of Type 1 Diabetes Mellitus
Keywords: AGEs; Aflibercept; CTAD; Denys-Drash syndrome; Diabetic nephropathy; ELISA; ERK; HIF; Nephropathy; Pegaptanib; PlGF; ROS; Rac; Ranibizumab; VEGF; VEGF Trap-Eye; VEGFRs; Vascular endothelial growth factor; albuminuria; angiogenesis; angiotensin converting enzyme (ACE); glomerular endotheliosis; glomerular filtration rate (GFR); glomerulosclerosis; hypertension; hypertrophy; microalbuminuria; nephritic syndrome; pathogenesis; proteinuria; renal hypoxia; sFlt-1; type 1 diabetes mellitus
Document Type: Research Article
Publication date: 2011-01-01
- Current Drug Targets aims to cover the latest and most outstanding developments on the medicinal chemistry and pharmacology of molecular drug targets e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal will be devoted to a single timely topic, with series of in-depth reviews, written by leaders in the field, covering a range of current topics on drug targets. These issues will be organized and led by a guest editor who is a recognized expert in the overall topic. As the discovery, identification, characterisation and validation of novel human drug targets for drug discovery continues to grow; this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.